In this regard, a recent pooled cross-sectional analysis using electronic health records from an integrated database including about 257 million US residents across 50 states explored prescribing trends for T1D patients who were prescribed GLP-1 RAs, the dual GIP/GLP-1 RA tirzepatide or SGLT2 inhibitors [146]. The gene discussed is GIP; the disease is type 1 diabetes mellitus.